Rulicent (Ruxolitinib) 5 mg & 10 mg Tablets — JAK Inhibitor for Myelofibrosis & Polycythemia Vera

Generic Name: Ruxolitinib (as Ruxolitinib Phosphate)
Brand/Trade Name: Rulicent
Available Strengths: 5 mg and 10 mg tablets
Pack Size: 14 tablets per box
Manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh
Drug Class: Janus Kinase (JAK1/JAK2) Inhibitor — Antineoplastic / Hematologic Agent
Route: Oral tablets
Prescription Required: Yes — For use only under hematologist or oncologist supervision

⚠️ Important Notice: Rulicent (Ruxolitinib) tablets are a prescription-only medicine used to treat serious blood disorders. This medicine must never be stopped abruptly without medical guidance, as doing so can cause a serious withdrawal reaction. Always take Rulicent exactly as prescribed by your hematologist.

What Is Rulicent (Ruxolitinib) 5 mg & 10 mg?

Some blood cancers don’t behave like the leukemias most people have heard of. Myelofibrosis and polycythemia vera are part of a group of conditions called myeloproliferative neoplasms (MPNs) — disorders where the bone marrow produces blood cells in a way that has gone fundamentally out of control. The result can be an enlarged spleen, debilitating fatigue, night sweats, and a quality of life that steadily erodes over time.

For more than a decade, Ruxolitinib has been the cornerstone treatment for these conditions.

According to Incyte’s original FDA approval announcement, Ruxolitinib became the first and only product ever approved by the FDA specifically for myelofibrosis, and the first drug in an entirely new class — JAK inhibitors — to receive any FDA approval at all. That was in November 2011. In the years since, its role has expanded into polycythemia vera and a serious post-transplant complication called graft-versus-host disease (GVHD).

Rulicent brings this same essential molecule — Ruxolitinib — to patients in Bangladesh and the surrounding region, manufactured by Incepta Pharmaceuticals Ltd., one of the country’s largest and most established pharmaceutical companies.

If you are also exploring related treatment options for blood cancers, you can browse our full Leukemia treatment category or our broader Oncology product range.

What Is Rulicent Prescribed For?

Rulicent (Ruxolitinib) tablets have four distinct FDA-studied indications. Each represents a different way that JAK signaling has gone wrong in the body — and Ruxolitinib’s job is to correct it.

1. Myelofibrosis (MF)

Rulicent is indicated for intermediate- or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults. As Incyte’s release describes, myelofibrosis is a potentially life-threatening blood cancer characterized by bone marrow failure, an enlarged spleen, and debilitating symptoms that severely affect daily life.

This was the original indication that brought Ruxolitinib to market, based on two landmark Phase 3 trials — COMFORT-I and COMFORT-II.

2. Polycythemia Vera (PV)

Rulicent is indicated for polycythemia vera in adults who have had an inadequate response to, or are intolerant of, hydroxyurea — the older standard treatment for this condition. This approval came in December 2014, based on the pivotal Phase 3 RESPONSE trial, which demonstrated superior hematocrit control and reductions in spleen volume compared with best available therapy.

3. Acute Graft-Versus-Host Disease (Steroid-Refractory)

For patients who have undergone an allogeneic stem cell transplant, GVHD occurs when donor immune cells attack the recipient’s own tissues. Rulicent is indicated for steroid-refractory acute GVHD in adults and children 12 years and older — meaning it is used specifically when corticosteroids, the first-line treatment, have failed to control the disease.

4. Chronic Graft-Versus-Host Disease (After Prior Therapy)

Rulicent is also indicated for chronic GVHD after failure of one or two prior lines of systemic therapy, in adults and children 12 years and older.

A note on these indications: Each one requires a confirmed diagnosis from a hematologist or transplant specialist before treatment begins. Ruxolitinib dosing differs meaningfully across these four conditions — your specialist will determine the correct starting dose based on your specific diagnosis and blood counts.

How Does Rulicent (Ruxolitinib) Work? (Mechanism of Action)

To understand Ruxolitinib’s mechanism, it helps to understand what actually goes wrong at the cellular level in conditions like myelofibrosis and polycythemia vera.

Deep inside blood-forming cells, a signaling pathway called JAK-STAT controls how cells respond to growth signals. Two enzymes in this pathway — JAK1 and JAK2 — relay messages that tell immature blood cells how fast to grow and divide. In healthy people, this signaling is tightly regulated.

In myeloproliferative neoplasms like myelofibrosis and polycythemia vera, this signaling becomes dysregulated — most commonly due to a mutation in the JAK2 gene itself (known as JAK2V617F), found in the majority of these patients. The result is a signaling pathway stuck in overdrive: the bone marrow produces blood cells uncontrollably, leading to an enlarged spleen, abnormal blood counts, and progressive scarring (fibrosis) of the bone marrow itself.

Ruxolitinib works by directly inhibiting both JAK1 and JAK2 enzymes. By blocking this pathway:

1. The excessive, dysregulated growth signal is interrupted
2. Spleen size is reduced as abnormal cell production slows
3. Disease-related symptoms — night sweats, fatigue, itching, abdominal discomfort — improve
4. In GVHD, the same JAK1/JAK2 blockade dampens the overactive immune signaling that drives donor cells to attack the recipient’s tissues

This mechanism doesn’t just manage symptoms — it addresses the abnormal signaling process believed to drive the underlying disease itself, which is why Ruxolitinib became the foundation of modern myelofibrosis treatment.

Clinical Trial Evidence — What the Data Shows

COMFORT-I and COMFORT-II (Myelofibrosis)

According to published trial documentation, COMFORT-I was a randomized, double-blinded Phase 3 study comparing Ruxolitinib against placebo in 309 patients with intermediate-2 or high-risk myelofibrosis. The primary endpoint — a reduction in spleen volume of at least 35% — was achieved by a significantly greater proportion of patients on Ruxolitinib.

Beyond spleen response, survival data presented at the 2011 ASH Annual Meeting showed that at a median follow-up of 51 weeks, there were 13 deaths (8.4%) in the Ruxolitinib group compared to 24 deaths (15.7%) in the placebo group — an early signal of a potential survival benefit alongside symptom control.

COMFORT-II, conducted across nine European countries, compared Ruxolitinib against best available therapy (hydroxyurea, steroids, or supportive care) and confirmed consistent spleen volume reductions across patient subgroups.

RESPONSE Trial (Polycythemia Vera)

The pivotal Phase 3 RESPONSE trial, conducted under a Special Protocol Assessment with the FDA, demonstrated that Ruxolitinib achieved superior hematocrit control and spleen volume reduction compared with best available therapy in PV patients who were resistant to or intolerant of hydroxyurea — the data that supported the 2014 expanded approval.

Dosage — How to Take Rulicent

Dosing varies significantly by indication. Never adjust your dose without your hematologist’s guidance.

For Myelofibrosis:

Per standard prescribing guidance, the starting dose is based on your platelet count:

• Platelet count >200 × 10⁹/L: 20 mg orally twice daily
• Platelet count 100–200 × 10⁹/L: 15 mg orally twice daily
• Platelet count 50 to <100 × 10⁹/L: 5 mg orally twice daily

For Polycythemia Vera:

• Starting dose: 10 mg orally twice daily

For Acute GVHD:

• Starting dose: 5 mg orally twice daily

For Chronic GVHD:

• Starting dose: 10 mg orally twice daily

How to Take Rulicent Correctly:

• Take tablets orally, with or without food
• Take at consistent times each day, approximately 12 hours apart for twice-daily dosing
• Swallow tablets whole, or they may be dispersed in water for patients unable to swallow whole tablets (confirm this approach with your pharmacist first)
• Your hematologist will monitor complete blood counts (CBC) every 2 to 4 weeks until your dose is stabilized, then periodically thereafter
• Dose adjustments are common in the early weeks of treatment as your specialist finds the right balance between symptom control and blood count safety

Critical safety point: Do not stop taking Rulicent abruptly. Stopping treatment suddenly can cause a rapid return of disease symptoms and, in rare cases, a serious withdrawal reaction involving high fever, cytokine release, and rapid clinical deterioration. If you need to stop treatment for any reason, your hematologist will guide a tapering plan.

Key Benefits of Rulicent for Patients

The foundation of modern myelofibrosis care: Ruxolitinib was the first drug ever approved specifically for myelofibrosis and remains the reference standard against which newer treatments are measured.

Meaningful spleen and symptom reduction: Clinical trial data consistently showed significant reductions in spleen volume alongside improvement in debilitating symptoms like night sweats, itching, and abdominal discomfort — improvements that directly affect day-to-day quality of life.

An option after hydroxyurea fails: For polycythemia vera patients who no longer respond to or cannot tolerate hydroxyurea, Rulicent offers a clinically validated next step rather than a therapeutic dead end.

A treatment option for steroid-refractory GVHD: For transplant patients whose graft-versus-host disease has not responded to first-line corticosteroids, Rulicent provides an additional treatment pathway at a critical point in care.

Decades of accumulated real-world clinical experience: Because Ruxolitinib has been used clinically since 2011, hematologists have extensive experience managing its dosing, side effects, and monitoring requirements — this maturity benefits patient safety.

Accessible manufacturing: Produced by Incepta Pharmaceuticals Ltd., one of Bangladesh’s most established pharmaceutical manufacturers, Rulicent makes long-term JAK inhibitor therapy financially reachable for patients who would otherwise face the high cost of the originator brand (Jakafi).

Side Effects — What Patients Should Know

Ruxolitinib has now been used clinically for well over a decade, giving hematologists a clear understanding of its safety profile. Side effects differ somewhat depending on which condition is being treated.

Most Common Side Effects (Myelofibrosis & Polycythemia Vera):

According to compiled clinical trial safety data, the most frequently reported side effects in MF and PV patients include low platelet counts, low red blood cell counts, bruising, dizziness, headache, and diarrhea.

Most Common Side Effects (Acute & Chronic GVHD):

For patients treated for acute GVHD, the most common adverse reactions include low platelet counts, low red or white blood cell counts, infections, and swelling. For chronic GVHD, the most common reactions include low red blood cell or platelet counts and infections, including viral infections.

Serious Side Effects — Require Close Monitoring:

⚠️ Low Blood Cell Counts (Cytopenias)
Thrombocytopenia (low platelets), anemia (low red blood cells), and neutropenia (low white blood cells) are the most clinically significant and closely monitored effects of Ruxolitinib. FDA labeling specifically instructs that thrombocytopenia should be managed by dose reduction or temporary interruption, with platelet transfusions used when necessary; anemia may require blood transfusions and dose adjustment.

⚠️ Serious Infections
Ruxolitinib can weaken the immune system’s ability to fight infection. Serious bacterial, mycobacterial (including tuberculosis), fungal, and viral infections have been reported. FDA guidance specifically states that therapy should be delayed until any active serious infection has resolved, and patients should be observed closely for signs of infection throughout treatment.

⚠️ Progressive Multifocal Leukoencephalopathy (PML)
A rare but serious brain infection has been associated with Ruxolitinib use. Any new neurological symptoms — confusion, vision changes, weakness, difficulty speaking — should be reported to your hematologist immediately for evaluation.

⚠️ Herpes Zoster (Shingles) and Hepatitis B Reactivation
Reactivation of dormant viral infections, including herpes zoster and hepatitis B, has been reported. Patients with a history of hepatitis B should discuss this with their hematologist before starting treatment.

⚠️ Non-Melanoma Skin Cancers
An increased risk of certain skin cancers — basal cell, squamous cell, and Merkel cell carcinoma — has been observed. Periodic skin examinations are recommended during treatment.

⚠️ Symptom Flare After Stopping Treatment
As noted above, stopping Ruxolitinib abruptly can cause a return of disease symptoms and, rarely, a serious cytokine-release type reaction. This is why tapering under medical guidance — never self-directed discontinuation — is essential.

⚠️ Elevated Cholesterol and Lipid Levels
Ruxolitinib may raise cholesterol, LDL, and triglyceride levels. Periodic lipid monitoring during treatment is typically recommended.

Important Warnings and Precautions

Tell your hematologist before starting Rulicent if you:

• Have a history of tuberculosis, hepatitis B, or herpes (cold sores, genital herpes, or shingles)
• Have any active infection
• Have liver or kidney disease
• Have a history of skin cancer
• Are pregnant, planning pregnancy, or breastfeeding
• Are taking any other prescription, over-the-counter, or herbal medications

Pregnancy and Breastfeeding:

The effects of Ruxolitinib on a developing pregnancy are not fully established in humans, and animal studies have shown potential for fetal harm. Discuss pregnancy planning with your hematologist before starting treatment. Ruxolitinib and its metabolites have been detected in breast milk; breastfeeding while taking this medicine should be discussed carefully with your specialist.

Children and Adolescents:

Safety and effectiveness in children have not been established for myelofibrosis or polycythemia vera. For acute and chronic GVHD specifically, Ruxolitinib is approved for patients 12 years and older.

Drug Interactions

Ruxolitinib is metabolized primarily by the CYP3A4 liver enzyme, making interactions with other CYP3A4-affecting medications clinically significant — often requiring dose adjustment rather than avoidance.

Strong CYP3A4 inhibitors (may require dose reduction):

• Ketoconazole, itraconazole, fluconazole (antifungals)
• Clarithromycin, erythromycin (antibiotics)
• Ritonavir, lopinavir (antiretrovirals)
• Per clinical guidance, when a strong CYP3A4 inhibitor is started in a patient already on Ruxolitinib, the dose is typically reduced by approximately 50%

CYP3A4 inducers (may reduce effectiveness):

• Rifampicin
• Carbamazepine, phenytoin
• St. John’s Wort

Other relevant interactions:

• Live vaccines are generally not recommended during treatment due to immune suppression
• Other CYP3A4 substrate medications may require monitoring for altered effect

Always provide your complete medication list — prescription, over-the-counter, and herbal — to your hematologist before starting Rulicent and at every follow-up visit.

Monitoring During Rulicent Treatment

Regular monitoring is a core part of safe Ruxolitinib therapy:

• Complete Blood Count (CBC): Before starting treatment, then every 2–4 weeks until your dose stabilizes, then periodically thereafter
• Liver and kidney function tests: Periodically, especially in patients with pre-existing liver or kidney disease
• Lipid panel: Periodic cholesterol and triglyceride monitoring
• Skin examinations: Periodic dermatologic checks given the association with non-melanoma skin cancers
• TB screening: Prior to starting treatment in patients with risk factors

Do not skip scheduled blood tests — early detection of cytopenias allows your hematologist to adjust your dose before complications develop.

How to Store Rulicent Tablets

• Store at room temperature, below 30°C
• Keep in a cool, dry place away from direct sunlight and moisture
• Store in the original blister packaging until ready to use
• Keep out of reach of children and pets
• Do not use tablets past the expiry date printed on the box
• Do not store in a bathroom or near a sink

About Incepta Pharmaceuticals Ltd.

Incepta Pharmaceuticals Ltd. is one of Bangladesh’s largest and most respected pharmaceutical manufacturers, with a broad portfolio spanning oncology, hematology, cardiology, and general medicine. Known for strong manufacturing standards and a wide distribution network across South Asia, Incepta has built a reputation for delivering complex specialty medicines reliably to patients who need them.

Rulicent reflects Incepta’s continued investment in hematology and oncology supportive care — bringing a clinically essential, decade-proven JAK inhibitor therapy within reach for patients across Bangladesh managing myelofibrosis, polycythemia vera, and graft-versus-host disease.

Related Medicines Available at 100Meds

Patients managing myeloproliferative neoplasms or post-transplant complications often require a range of supportive and targeted therapies. The following products on our platform may also be relevant:

• Generic Venetoclax 100 mg — A BCL-2 inhibitor used in certain blood cancers, often relevant for patients with overlapping hematologic conditions
• Ivosenib 250 mg (Ivosidenib) — An IDH1 inhibitor for AML, another targeted oral therapy in our hematology-oncology range
• Ruxonib Cream 1.5% (Topical Ruxolitinib) — Note: this is a different formulation of the same active molecule, used topically for vitiligo and atopic dermatitis — not interchangeable with oral Rulicent tablets
• Browse our full Leukemia & Blood Cancer range →

These products are listed for informational reference only. Treatment selection must always be determined by your hematologist based on your specific diagnosis.

Frequently Asked Questions About Rulicent (Ruxolitinib)

Q: What is the generic name of Rulicent?
The generic (INN) name is Ruxolitinib, supplied as ruxolitinib phosphate. Rulicent is the brand name manufactured by Incepta Pharmaceuticals Ltd. in Bangladesh. The original branded version, developed by Incyte Corporation, is sold internationally as Jakafi.

Q: Is Rulicent the same as the Ruxolitinib cream used for vitiligo?
No — and this distinction matters. Rulicent is an oral tablet used for myelofibrosis, polycythemia vera, and GVHD, dosed at 5–20 mg taken by mouth. Topical Ruxolitinib cream (such as Ruxonib Cream 1.5%) is a completely different formulation, applied to the skin, used for vitiligo and atopic dermatitis. They are not interchangeable, and the oral tablet carries a substantially different and more significant side effect profile due to systemic absorption.

Q: What is the difference between Rulicent 5 mg and 10 mg?
The dose your hematologist prescribes depends entirely on your specific diagnosis and, for myelofibrosis, your platelet count. The 5 mg strength is typically used as a starting dose for myelofibrosis patients with lower platelet counts or for acute GVHD, while 10 mg is the standard starting dose for polycythemia vera and chronic GVHD. Your specialist will determine and adjust your exact dose over time.

Q: Can I stop taking Rulicent if I feel better?
No. Stopping Ruxolitinib abruptly can cause a rapid return of your underlying disease symptoms and, in rare cases, a serious reaction involving fever and rapid clinical decline. Always consult your hematologist before making any change to your treatment, even if you are feeling well.

Q: How is Rulicent different from chemotherapy?
Rulicent is a targeted JAK inhibitor, not conventional chemotherapy. It works by specifically blocking JAK1 and JAK2 signaling enzymes that drive abnormal blood cell production in myeloproliferative neoplasms, rather than broadly attacking all rapidly dividing cells.

Q: What is the price of Rulicent 5 mg / 10 mg at 100Meds?
Pricing varies based on quantity, strength, and regional availability. Please use the Inquire Now button or contact us via WhatsApp/Telegram for current pricing tailored to your prescription.

Q: Is it safe to order Rulicent online from 100Meds?
100Meds operates as a verified pharmaceutical sourcing platform with transparent, documented supply chains. We do not dispense prescription medicines without proper documentation. Contact our team and we will guide you through the process safely.

A Note to Patients and Caregivers

A diagnosis of myelofibrosis, polycythemia vera, or steroid-refractory GVHD brings with it a particular kind of exhaustion — not just the physical symptoms, but the ongoing vigilance these conditions demand. Regular blood tests. Dose adjustments. The careful balance between controlling disease and managing side effects.

Rulicent does not erase that complexity. But it offers something that has helped tens of thousands of patients worldwide since 2011: a clinically established, well-understood treatment that addresses the abnormal signaling driving these diseases, with over a decade of real-world data behind it.

At 100Meds, we understand that long-term specialty medicines like Rulicent represent both a medical and financial commitment. Our role is to help you access this medication reliably, affordably, and with full transparency — for as long as your treatment plan requires it.

Reach out to our team today for pricing, availability, and ordering assistance.

This page is for informational purposes only and does not constitute medical advice. Rulicent (Ruxolitinib) is a prescription-only medication. All treatment decisions, including starting, stopping, or adjusting your dose, must be made in consultation with a qualified hematologist or oncologist.